Beam Therapeutics

ISIN US07373V1052

 | 

WKN A2PY7P

Market cap (in EUR)
2,435 m
Country
United States
Sector
Healthcare
Dividend yield
0.00%
 

Overview

Description

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.
Show more Show less
Healthcare Biopharmaceuticals Other Biopharmaceuticals United States

Financials

Key metrics

Market capitalisation, EUR 2,435 m
EPS, EUR -4.02
P/B ratio 2.9
P/E ratio -
Dividend yield 0.00%

Income statement (2024)

Revenue, EUR 59 m
Net income, EUR -348 m
Profit margin -593.13%

What ETF is Beam Therapeutics in?

There are 4 ETFs which contain Beam Therapeutics. All of these ETFs are listed in the table below. The ETF with the largest weighting of Beam Therapeutics is the iShares Nasdaq US Biotechnology UCITS ETF USD (Dist).
ETF Weight Investment focus Fund size (in m EUR)
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) 0.21%
Equity
United States
Health Care
Biotech
46
Vanguard ESG Global All Cap UCITS ETF (USD) Distributing 0.00%
Equity
World
Social/Environmental
495
Vanguard ESG North America All Cap UCITS ETF (USD) Distributing 0.00%
Equity
North America
Social/Environmental
27
JPMorgan BetaBuilders US Small Cap Equity UCITS ETF USD (dist) 0.04%
Equity
United States
Small Cap
182
— Data provided by Trackinsight, etfinfo, Xignite Inc., gettex, FactSet and justETF GmbH.

Quotes are either real-time (gettex) or 15 minutes delayed stock exchange quotes or NAVs (daily published by the fund provider). By default, ETF returns include dividend payments (if applicable). There is no warranty for completeness, accuracy and correctness for the displayed information.